Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging

Jinling Hospital, China350 enrolled

Overview

To evaluate the efficacy of multi-modality magnetic resonance quantitative parameters in evaluating the treatment effects of high-grade gliomas, and to provide new biomarkers for the establishment of new diagnostic criteria for the identification of true and pseudoprogression of high-grade gliomas.

Study Type

OBSERVATIONAL

Enrollment

350

Conditions

Glioma

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with high-grade gliomas confirmed by pathology and have not been treated with concurrent chemoradiotherapy; 2. Written informed consent is obtained. Exclusion Criteria: 1. Patients not suitable for enhanced MRI scanning of patients; 2. Patients who have not finished follow-up concurrent chemoradiotherapy or MR scanning.

Locations (1)

Jinling Hospital

Nanjing, Jiangsu, China

RECRUITING

Outcomes

Primary Outcomes

Ktrans

The volume transfer constant in dynamic contrast-enhanced MR Imaging

Time frame: baseline

Ktrans

The volume transfer constant in dynamic contrast-enhanced MR Imaging

Time frame: 3 months

Ktrans

The volume transfer constant in dynamic contrast-enhanced MR Imaging

Time frame: 10 months

Central Contacts

Yuan Xie, Master

CONTACT

+86 13584099838 cheryl050914@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.